Dr. Aguirre-Ghiso and colleagues determined that when breast cancer DCCs spread to the lung's air sacs (alveoli), they are kept in a dormant state by immune cells known as alveolar macrophages.

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve survival compared with placebo in patients with locally advanced squamous cell ...